Abstract:Key Points Parkinson's disease is a progressive neurological disorder characterized primarily by motor symptoms that include rigidity, hypokinesia and tremor. The most pronounced neuropathological feature is a loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in dopamine levels in the target region, the striatum. In the substantia nigra, some neurons have intracytoplasmic inclusions known as Lewy bodies. In most patients, Parkinson's disease shows no clear inheritance and the cause of neurodegeneration is not known. Several disease mechanisms have been proposed, including oxidative stress and mitochondrial dysfunction. Some emphasis has been placed on the possibility that environmental toxins trigger these pathological changes. In the late 1990s, the discovery of the gene that causes a rare autosomal-dominant form of Parkinson's disease led to renewed interest in the search for pathogenic mechanisms. The mutated gene encodes α-synuclein, a synaptic protein of unknown function. It has been suggested that it plays a role in the recycling of vesicles that have released their neurotransmitter content into the synaptic cleft. Moreover, further rare forms of Parkinson's disease have been identified that result from mutations in parkin and ubiquitin carboxy-terminal hydrolase L1. These proteins participate in the ubiquitin–proteasome pathway, which is responsible for the degradation of unwanted proteins. We speculate why changes in these diverse genes lead to a neurodegenerative process that is relatively focused on dopamine-containing neurons, and emphasize the role of dopamine-dependent oxidative stress in this process. We believe that there are multiple aetiological triggers, resulting from either genetic changes or environmental insults, which share the same final common pathway to cell death in dopaminergic neurons. Increased levels of cytoplasmic dopamine in nigral neurons in Parkinson's disease patients might result in dopamine oxidation and the generation of reactive oxygen species that can damage and eventually kill these neurons. One pathway that might lead to these events involves impaired vesicular storage of dopamine. Recent experimental evidence shows that the expression of mutant α-synuclein in a human dopaminergic cell line increases cytoplasmic dopamine levels and raises the levels of superoxide radicals in the cytoplasm. Dopamine-induced oxidative stress, impaired synaptic vesicle function and misfolding of α-synuclein, due to mutations or to oxidative damage to this protein, might be components in a self-perpetuating vicious cycle that eventually leads to the demise of dopaminergic neurons.

A Brief Overview of Tyrosine Hydroxylase and alpha-Synuclein in the Parkinsonian Brain

A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

An Overview on the Role of Α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics

From Pathogenesis to Therapeutic Prospects

The role of tyrosine hydroxylase–dopamine pathway in Parkinson's disease pathogenesis

Alpha-Synuclein Aggregation in Parkinson's Disease

Human tyrosine hydroxylase in Parkinson’s disease and in related disorders

Ignored Avenues in Alpha-Synuclein Associated Proteopathy

Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinson’s Disease

Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia

Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson's Disease

Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease

Small Molecules, α-Synuclein Pathology, and the Search for Effective Treatments in Parkinson's Disease

Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

The Role of α-Synuclein Oligomers in Parkinson’s Disease

Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease

The phosphorylation of α‐synuclein: development and implication for the mechanism and therapy of the Parkinson's disease

Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein